Skip to main content
A consortium led by Wake Forest and Rice University secured 24.8 million dollars from ARPA-H to develop bioprinted, vascularized kidney tissues.
Funding
1 min read

A consortium led by Wake Forest and Rice University secured 24.8 million dollars from ARPA-H to develop bioprinted, vascularized kidney tissues.

Originally reported by news-medical.net

A consortium led by Wake Forest and Rice University secured 24.8 million dollars from ARPA-H to develop bioprinted, vascularized kidney tissues. This five-year initiative aims to manufacture personalized organs using a patient鈥檚 own cells for 120,000 people on waiting lists. The project focuses on creating a library of complex bioinks that mimic tissue environments and sustain cell viability. This shifts the healthcare model from organ matching to on-demand manufacturing without the need for lifelong immunosuppressive drugs. 馃К馃彞 #Bioprinting #3DPrinting #HealthTech #ARPAH

This article is an AI-assisted rewrite of the linked source report. Facts originate from the source; phrasing is AMPulse's. Use Read Original below to verify, or Report an issue if something is wrong.

Read Original

How This Connects

6 related events
  1. Same pattern

    Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.

  2. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  3. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  4. This article

    A consortium led by Wake Forest and Rice University secured 24.8 million dollars from ARPA-H to develop bioprinted, vascularized kidney tissues.

  5. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  6. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.